EDAP TMS SA (EDAP +15.5%) gets a pop after submitting its Pre-Market Approval Application to the...

|About: EDAP TMS S.A. (EDAP)|By:, SA News Editor

EDAP TMS SA (EDAP +15.5%) gets a pop after submitting its Pre-Market Approval Application to the FDA for Ablatherm-HIFU, a high intensity ultrasound for the treatment of low risk, localized prostate cancer. Included in EDAP's submission is positive data from its Phase 3 clinical trials and encouraging statistics from its worldwide database of treatment information and follow-up data from patients who have already undergone the therapy.